Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced that Royal Columbian Hospital (RCH) has dosed its first patient in the ongoing Phase 2 trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).
According to Arch, RCH, part of Fraser Health, is the fourth site to dose patients in Canada. Patient recruitment into the trial is ongoing at Toronto General Hospital, part of University Health Network, St. Michael’s Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine.
In a statement, Richard Muruve, CEO of Arch, commented, “RCH dosing its first patient is another meaningful step forward for the company’s Phase 2 CS-AKI trial. Arch continues to make steady progress toward the goals of the study and establishing LSALT peptide as a new drug to reduce the incidence of AKI and the need for dialysis and kidney transplants.”
